Dihexa

• Dry-fill capsules
• 30mL liquid solution
• Transdermal gel
• 1 gram powder

Research indicates Dihexa may: These mechanisms make it of interest in cognitive, neurodegenerative, and injury-repair research models.

• Bind to HGF and facilitate functional activation of the HGF c Met pathway, supporting pro synaptogenic signaling
• Support synaptogenesis and dendritic spine related endpoints associated with learning and memory in impaired model designs
• Promote neurotrophic like downstream effects (often framed as network repair and connectivity restoration in mechanistic discussions)
• Demonstrate apparent BBB penetration and metabolic stability features in preclinical pharmacokinetic work

Dihexa is commonly researched for

• Improved learning and memory performance endpoints in animal models of cognitive dysfunction (not consistently seen in unimpaired models)
• Increased synapse and spine density markers in hippocampal related readouts in preclinical research
• Potential neurorepair oriented signaling via HGF c Met activation, which is why fosgonimeton (a prodrug approach) has been studied clinically for neurodegenerative indications

• Dihexa has no well established long term human safety profile, and evidence is largely preclinical. A key theoretical concern discussed in the literature is that HGF c Met signaling is implicated in oncogenic biology in some contexts, which is why tumorigenesis and cancer progression risk is often raised as an uncertainty rather than a confirmed outcome.
• Reported tolerability discussions commonly mention mild CNS or GI type effects as possibilities (for example restlessness, headache, or nausea), but systematic safety data remain limited and should be treated as incomplete.